

Table S1: Summary of all adverse events

Number (percentage) of participants reporting AE, by treatment group.

System Organ Class Preferred Term	Placebo n = 25	GSK2798745 n = 22
General disorders and administration site conditions	6 (24)	4 (18)
Pyrexia	3 (12)	4 (18)
Influenza-like illness	1 (4)	1 (5)
Chest discomfort	1 (4)	0
Chills	0	1 (5)
Pain	1 (4)	0
Nervous system disorders	5 (20)	3 (14)
Headache	5 (20)	3 (14)
Respiratory, thoracic and mediastinal disorders	2 (8)	2 (9)
Cough	0	1 (5)
Dyspnoea	0	1 (5)
Epistaxis	0	1 (5)
Oropharyngeal pain	0	1 (5)
Pulmonary pain	1 (4)	0
Rhinorrhoea	1 (4)	0
Infections and infestations	3 (12)	0
Nasopharyngitis	3 (12)	0
Ear and labyrinth disorders	1 (4)	0
Vertigo	1 (4)	0
Gastrointestinal disorders	1 (4)	0
Odynophagia	1 (4)	0
Injury, poisoning and procedural complications	0	1 (5)
Burns second degree	0	1 (5)
Investigations	1 (4)	0
Alanine aminotransferase increased	1 (4)	0